NO20070070L - Ultralydkontrastmiddeldoseringsformulering - Google Patents

Ultralydkontrastmiddeldoseringsformulering

Info

Publication number
NO20070070L
NO20070070L NO20070070A NO20070070A NO20070070L NO 20070070 L NO20070070 L NO 20070070L NO 20070070 A NO20070070 A NO 20070070A NO 20070070 A NO20070070 A NO 20070070A NO 20070070 L NO20070070 L NO 20070070L
Authority
NO
Norway
Prior art keywords
microparticles
dosage formulation
vial
dry powder
body weight
Prior art date
Application number
NO20070070A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Walowitch
Howard Bernstein
Iii Donald E Chickering
Julie Staub
Original Assignee
Acusphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acusphere Inc filed Critical Acusphere Inc
Publication of NO20070070L publication Critical patent/NO20070070L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Acoustics & Sound (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
NO20070070A 2004-06-04 2007-01-04 Ultralydkontrastmiddeldoseringsformulering NO20070070L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/017813 WO2005120587A1 (en) 2004-06-04 2004-06-04 Ultrasound contrast agent dosage formulation

Publications (1)

Publication Number Publication Date
NO20070070L true NO20070070L (no) 2007-03-05

Family

ID=34958128

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070070A NO20070070L (no) 2004-06-04 2007-01-04 Ultralydkontrastmiddeldoseringsformulering

Country Status (10)

Country Link
JP (1) JP4808214B2 (zh)
CN (1) CN1993147B (zh)
AU (1) AU2004320514B8 (zh)
BR (1) BRPI0418879A (zh)
CA (1) CA2569134C (zh)
IL (2) IL179594A (zh)
MX (1) MXPA06014111A (zh)
NO (1) NO20070070L (zh)
RU (1) RU2344833C2 (zh)
WO (1) WO2005120587A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630028B2 (en) * 2006-08-11 2017-04-25 Koninklijke Philips N.V. Ultrasound system for cerebral blood flow imaging and microbubble-enhanced blood clot lysis
KR101061224B1 (ko) * 2008-10-08 2011-08-31 포항공과대학교 산학협력단 Ｘ 선을 이용한 유동정보 측정용 캡슐
US8784800B2 (en) 2009-03-09 2014-07-22 Medtronic, Inc. Method of delivering cell therapy to a target site
US9757462B2 (en) 2010-11-19 2017-09-12 Sapporo Medical University Combined pharmaceutical preparation
EP2844362B1 (en) * 2012-04-30 2020-02-26 Ge Healthcare As Method for filling a container with a foamable composition
ES2821966T3 (es) 2014-04-02 2021-04-28 Nitto Denko Corp Molécula de direccionamiento derivada de RBP y utilización de la misma
ES2890328T3 (es) * 2015-04-20 2022-01-18 Univ California Gas encapsulado o material de contraste de CT de vacío parcial
RU2620758C1 (ru) * 2016-07-13 2017-05-29 Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) Способ количественного определения микрососудов в атеросклеротической бляшке сонных артерий
CN111419181B (zh) * 2020-03-31 2023-07-25 浙江大学 一种用于小动物长时间活体成像的装置及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
CN1068229C (zh) * 1993-12-15 2001-07-11 勃勒柯研究有限公司 超声对比介质、含该介质的对比剂及方法
DE4406474A1 (de) * 1994-02-23 1995-08-24 Schering Ag Gas enthaltende Mikropartikel, diese enthaltende Mittel, deren Verwendung in der Ultraschalldiagnostik, sowie Verfahren zur Herstellung der Partikel und Mittel
DE69729088T2 (de) * 1996-03-05 2005-05-12 Acusphere, Inc., Cambridge Mikroverkapselte fluorierte gase zur anwendung als bilderzeugende mittel
US5976501A (en) * 1996-06-07 1999-11-02 Molecular Biosystems, Inc. Use of pressure resistant protein microspheres encapsulating gases as ultrasonic imaging agents for vascular perfusion
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
US6045777A (en) * 1997-06-30 2000-04-04 Acusphere, Inc. Method for enhancing the echogenicity and decreasing the attenuation of microencapsulated gases

Also Published As

Publication number Publication date
RU2344833C2 (ru) 2009-01-27
JP4808214B2 (ja) 2011-11-02
IL213897A0 (en) 2011-07-31
JP2008501684A (ja) 2008-01-24
IL179594A0 (en) 2007-05-15
CN1993147A (zh) 2007-07-04
CN1993147B (zh) 2013-03-06
WO2005120587A1 (en) 2005-12-22
AU2004320514B2 (en) 2009-08-06
IL213897A (en) 2013-07-31
IL179594A (en) 2011-08-31
MXPA06014111A (es) 2007-03-07
CA2569134A1 (en) 2005-12-22
CA2569134C (en) 2010-11-23
RU2006147232A (ru) 2008-07-20
AU2004320514B8 (en) 2009-08-27
BRPI0418879A (pt) 2007-11-27
AU2004320514A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
NO20070070L (no) Ultralydkontrastmiddeldoseringsformulering
Li et al. In situ sprayed starvation/chemodynamic therapeutic gel for post‐surgical treatment of IDH1 (R132H) glioma
Tobudic et al. Antifungal susceptibility of Candida albicans in biofilms
ES2870028T3 (es) Composiciones y sus usos para el tratamiento de la diabetes y afecciones relacionadas al controlar el nivel de glucosa en sangre
McQuiston et al. Paradoxical roles of alveolar macrophages in the host response to Cryptococcus neoformans
Daikos et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use
NO20075046L (no) Gastroresistente farmasoytiske formuleringer inneholdende rifaximin
Chen et al. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model
Ho et al. COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
ES2773834T3 (es) Métodos y composiciones para tratar la depresión usando ciclobenzaprina
ES2955711T3 (es) Regímenes de dosificación para el tratamiento de infecciones fúngicas
Wellhöner et al. Eradication of chronic HCV infection: Improvement of dysbiosis only in patients without liver cirrhosis
Eduardo et al. Determination of the Effectiveness of Chlorine Dioxide in the Treatment of COVID 19
Krishna et al. Similar degrees of obesity induced by diet or aging cause strikingly different immunologic and metabolic outcomes
DK1609483T3 (da) Kontrastmiddel til ultralyd
Boros et al. Production and Signaling of Methane
Qiu et al. A novel strategy for antimicrobial agent: Role of exogenous carbon monoxide on suppressing Escherichia coli vitality and toxicity.
ES2539160T3 (es) Procedimiento de tratamiento de cáncer gástrico
Waterman et al. Aspirin promotes low density lipoprotein susceptibility to oxidative modification in healthy volunteers
Bhavnani et al. 733. Pharmacokinetic–pharmacodynamic (PK–PD) analyses for alanine aminotransferase (ALT) using phase 3 data from omadacycline (OMC)-treated patients
CN104095863B (zh) 一种包含唑来膦酸的药物组合物及其制剂
Tozzi et al. Biological Relevance of Intestinal Gases in Healthy Humans
Turcani et al. Tedisamil attenuates foetal transformation of myosin in the hypertrophied rat myocardium
Gunderson et al. 2: Tranexamic Acid Is Associated With Decreased Intraoperative Blood Loss And Wound Healing Complication Rate In Penile Inversion Vaginoplasty
Kanafani et al. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.